|
Mar 8
|
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023
|
|
Mar 8
|
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
|
|
Jan 11
|
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
|
|
Jan 8
|
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
|
|
Jan 2
|
XOMA Announces Stock Repurchase Program of up to $50 Million
|
|
Dec 20
|
XOMA Declares Quarterly Preferred Stock Dividends
|
|
Dec 19
|
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
|
|
Nov 7
|
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
|
|
Sep 6
|
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
|
|
Jun 23
|
XOMA Added to the Russell 2000® and Russell 3000® Indexes
|